Table 2. Comparison of Different Results From the Literature of the Last 15 Years [2, 6, 9, 10, 13-17].

Authors	Equivalent dose EQD2	Percentage of 2-year survival
Kramer et al* [13]	24	3
Present study	26	0
Sundstrom et al* [6]	26	8
Schroder et al [14]	31	2
Kramer et al* [13]	33	7
Present study	33	7
Nawrocki et al* [15]	33	6
Erridge et al* [2]	33	8
Jeremic et al* [16]	42	9
Present study	45	11
Sundstrom et al* [6]	45	13
Sundstrom et al* [6]	50	10
Schroder et al [14]	52	5
Janssen et al [9]	31 - 46	15
Janssen et al [9]	47 - 52	20
Van Oorschot et al [10]	42 - 49	10
Jeremic et al* [16]	17 or 24 (+platinum-based chemo)	12 (no stage IV in this study)
Nawrocki et al* [15]	33 (+cisplatin/vinorelbine)	24 (no stage IV in this study)
Strom et al* [17]	45 (+carboplatin/vinorelbine)	28 (no stage IV in this study)

*Randomized study.